# Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol

> **NCT01120964** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asklepion Pharmaceuticals, LLC** · enrollment: 22 (actual)

## Conditions studied

- Atrial Septal Defect
- Ventricular Septal Defect
- Atrioventricular Septal Defect

## Interventions

- **DRUG:** Intravenous L-Citrulline
- **DRUG:** Placebo of Intravenous L-Citrulline

## Key facts

- **NCT ID:** NCT01120964
- **Lead sponsor:** Asklepion Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01120964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01120964, "Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01120964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*